Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
EVMN vs OMER: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
OMER Captures Overall Composite Edge (54.1 HOLD vs 30.0 SELL), While EVMN Leads 3–2 on Growth & Valuation Pillars
OMER Overall Winner
6-Pillar Tally: EVMN 3 – 2 OMER (1 Tie)
Matrix Metrics: EVMN 2 – 8 OMER
As of Nov 16, 2026, Omeros Corporation (OMER) captures the overall head-to-head institutional edge over Evommune, Inc. (EVMN) on higher Unified Composite conviction (54.1/100 HOLD vs. 30.0/100 SELL) after splitting the core matrix 8–2 (led by Valuation Multiples, Growth & Scale), while EVMN wins 3–2 across the 6-pillar growth and valuation breakdown. EVMN trades at $7.10 (N/M Forward P/E, 0.0% operating margin) versus OMER at $16.68 (73.0x Forward P/E, -189.5% operating margin).
- Growth vs. Quality Trade-Off: OMER earns the overall head-to-head edge with a stronger Unified Composite Score (54.1/100 HOLD vs. EVMN 30.0/100 SELL) and 1.82β · 54% Vol risk profile, whereas EVMN leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About EVMN vs OMER
EVMN
Evommune, Inc.
$7.10
-6.95% 1D
Market Cap
$315.5M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.05β · 118% Vol
Unified Composite Score
30.0
SELL
Tech 50.0
Fund 35.0
Flow 69.0
Mom 44.0
Weinstein Technical Phase
Neutral · Hold
OMER
Head-to-Head Winner
Omeros Corporation
$16.68
-4.63% 1D
Market Cap
$1.3B
TTM Revenue
$27M
Forward P/E
73.0x
Beta / 30D Vol
1.82β · 54% Vol
Unified Composite Score
54.1
HOLD
Tech 44.0
Fund 55.0
Flow 74.0
Mom 50.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (EVMN 3 – 2 OMER)
1. Valuation Multiples
OMER
Forward P/E
N/M
73.0x
Trailing P/E
N/M
14.3x
PEG Ratio
N/M
0.81x
EV / Revenue
N/M
50.1x
2. Growth & Scale
OMER
Revenue Growth (YoY)
+0.0%
+14.9%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$27M
Market Cap
$315.5M
$1.3B
3. Profitability & Quality
EVMN
Gross Margin
N/A
38.3%
Operating Margin
0.0%
-189.5%
Net Profit Margin
0.0%
324.9%
Return on Equity (ROE)
-69.5%
-576.3%
4. Balance Sheet & Cash Flow
EVMN
Cash Generation (TTM)
-$75M
-$49M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$52M Net Cash
$97M Net Debt
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
EVMN
Options Structure Phase
SURGE
CONSOLIDATION
Current IV / %ile
209.0% (53rd %ile)
85.5% (28th %ile)
Put/Call OI Skew
N/A
0.09x (Call-Skewed)
OBV Trend / Tech Phase
ACCUMULATION · Neutral
DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: EVMN (2) vs OMER (8)| Institutional Metric | EVMN | OMER | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $315.5M | $1.3B | OMER | |
| Trailing P/E Ratio | N/M | 14.3x | OMER | |
| Forward P/E Ratio | N/M | 73.0x | OMER | |
| Revenue Growth (YoY) | +0.0% | +14.9% | OMER | |
| Operating Margin (TTM) | 0.0% | -189.5% | EVMN | |
| Net Profit Margin | 0.0% | 324.9% | OMER | |
| Return on Equity (ROE) | -69.5% | -576.3% | EVMN | |
| 52-Week Range Position | 8% ($5–$33) | 70% ($6–$21) | OMER | |
| Beta / 30D Volatility | 1.05β · 118% Vol | 1.82β · 54% Vol | OMER | |
| Unified Institutional Score | 30.0 / 100 (SELL) | 54.1 / 100 (HOLD) | OMER | |
| Trailing 12M Revenue (USD) | N/A | $27M | Scale | |
| Gross Profit Margin (TTM) | N/A | 38.3% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | 0.81x PEG · 50.1x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$75M ($52M Net Cash) | -$49M ($97M Net Debt) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
EVMN +34.37 pp
3M Horizon
OMER +47.1 pp
6M Horizon
OMER +110.13 pp
1Y Horizon
OMER +226.64 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | EVMN Revenue | OMER Revenue | EVMN Op. Margin | OMER Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2015 | N/A | $10M | N/A | -527.3% | OMER |
| FY2016 | N/A | $40M | N/A | -130.4% | OMER |
| FY2017 | N/A | $60M | N/A | -67.7% | OMER |
| FY2018 | N/A | $30M | N/A | -375.7% | OMER |
| FY2019 | N/A | $110M | N/A | -130.6% | OMER |
| FY2020 | N/A | $70M | N/A | -212.6% | OMER |
| FY2024 | $10M | N/A | -1000.2% | N/A | EVMN |
| FY2025 | $10M | N/A | -623.6% | N/A | EVMN |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
EVMN
SURGE
Current IV
209.0%
IV Percentile
53rd %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact EVMN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
OMER
CONSOLIDATION
Current IV
85.5%
IV Percentile
28th %ile
Put/Call OI Skew
0.09x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact OMER Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
EVMN Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
OMER Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ EVMN vs OMER Key Questions & Quantitative Answers
As of Nov 16, 2026, Omeros Corporation (OMER) captures the overall head-to-head institutional edge over Evommune, Inc. (EVMN) on higher Unified Composite conviction (54.1/100 HOLD vs. 30.0/100 SELL) after splitting the core matrix 8–2 (led by Valuation Multiples, Growth & Scale), while EVMN wins 3–2 across the 6-pillar growth and valuation breakdown. EVMN trades at $7.10 (N/M Forward P/E, 0.0% operating margin) versus OMER at $16.68 (73.0x Forward P/E, -189.5% operating margin). Growth vs. Quality Trade-Off: OMER earns the overall head-to-head edge with a stronger Unified Composite Score (54.1/100 HOLD vs. EVMN 30.0/100 SELL) and 1.82β · 54% Vol risk profile, whereas EVMN leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
OMER leads the Growth & Scale pillar: EVMN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with OMER at +14.9% YoY revenue growth and +0.0% YoY earnings growth on $27M TTM revenue (38.3% gross margin, -189.5% operating margin). Across the 8-period historical trajectory (FY2015 to FY2025), EVMN cumulative revenue shifted +0.0% while OMER shifted +600.0%. In operating R&D and SG&A reinvestment, EVMN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OMER.
OMER screens cheaper on headline valuation multiples. EVMN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas OMER trades at 73.0x Forward P/E, 14.3x Trailing P/E, 0.81x PEG, and 50.1x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EVMN (-69.5% ROE) versus OMER (-576.3% ROE) capital efficiency.
In options market volatility and institutional positioning, EVMN carries 209.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.05β · 118% Vol realized risk). By comparison, OMER carries 85.5% implied volatility (28th %ile, Balanced (25th–60th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.82β · 54% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
OMER vs EVMN · Reverse Pair
EVMN vs MPLT
· Sector Peer
EVMN vs ALMS
· Sector Peer
EVMN vs MAZE
· Sector Peer
OMER vs OCUL
· Sector Peer
OMER vs PTCT
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem